Table 1.
Characteristics of included studies.
| References | Study design | Setting | No. of patients | Age of participants (years)* | Manufactures of HIFU | Outcomes of interests (duration of follow-up after treatment) |
|---|---|---|---|---|---|---|
| Taran et al. (17) | Non-RCT | 14 medical centers in USA, Israel, UK and Germany | HIFU:109 HYS: 83 |
HIFU:44.8 ± 4.9; HYS:44.4 ± 5.6 |
InSightec | Fever (2 days) |
| Meng et al. (16) | RCT | China | HIFU: 50 RFA: 50 |
HIFU:35.6 ± 6.0; RF:39.2 ± 5.7 |
Shanghai Aishen Technology | Fever (2 days) |
| Chen et al. (12) | Non-RCT | China | HIFU: 30 MYO(abdominal/laparoscopic MYO):30 HYS: 30 |
HIFU:38.8; MYO:38.4; HYS:39.1 |
Chongqing Haifu Technology | Change of serum sex hormones (6 months) |
| Froeling et al. (13) | Retrospectivecohort study | Germany | HIFU: 36 UAE: 41 |
HIFU:36.2(29.2–41.0); UAE:42.7(33.6–52.2) |
InSightec | Rate of re-intervention (60.7–61.9 months) |
| Liu et al. (15) | Non-RCT | China | HIFU: 30 HYS: 30 |
HIFU:39.25 ± 3.08; HYS:41.13 ± 3.22 |
Chongqing Haifu Technology | Change of serum sex hormones (1 year) |
| Wang et al. (18) | RCT | China | HIFU: 60 MYO (abdominal MYO): 60 |
HIFU:39.92 ± 5.07; MYO:38.60 ± 4.36 |
Chongqing Haifu Technology | Fever (3 days) |
| Ikink et al. (14) | Retrospective cohort study | Netherlands | HIFU: 51 UAE: 68 |
HIFU:46(43–49); UAE:43(41–46) |
Philips Healthcare | Rate of re-intervention (1 year) |
| Wang et al. (23) | Non-RCT | China | HIFU: 89 MYO (laparoscopic MYO): 41 |
HIFU:37.9 ± 5.5; MYO:38.4 ± 5.0 |
Chongqing Haifu Technology | Days of hospital stay; Fever (2 days); Major adverse events (42 days) |
| Wang et al. (24) | Non-RCT | China | HIFU: 86 HYS: 81 |
HIFU:33.6 ± 4.6; HYS:34.1 ± 4.7 |
Chongqing Haifu Technology | Fever (2 days); Major adverse events (42 days) |
| Xu et al. (26) | Non-RCT | China | HIFU: 30 MYO (laparoscopic MYO): 34 |
Both groups:37.7 | Chongqing Haifu Technology | Change of serum sex hormones (6 months) |
| Barnard et al. (19) * | Prospective cohort study | USA | HIFU: 43 UAE: 40 |
HIFU:44.0 ± 4.3; UAE:44.3 ± 5.2 |
InSightec | Rate of re-intervention (42 days); Major adverse events (42 days) |
| Lin et al. (22) | Non-RCT | China | HIFU: 60 UAE: 54 |
HIFU:39.5 ± 7.4; UAE: 38.7 ± 6.2 |
Chongqing Haifu Technology | Incidence of abnormal pregnancy (2 years); Change of serum sex hormones (2 years); Fever (2 days) |
| Xiong et al. (25) | Retrospective cohort study | China | HIFU: 206 MYO (laparoscopic MYO): 317 |
HIFU:41.37 ± 5.68; MYO:40.48 ± 5.58 |
Chongqing Haifu Technology | Rate of re-intervention (1.5–4 years); Incidence of abnormal pregnancy (1.5–4 years); Days of hospital stay |
| Chen et al. (20) | Prospective cohort study | China | HIFU: 1,353 MYO (abdominal/laparoscopic MYO): 586 HYS: 472 |
HIFU:41.31 ± 5.08; MYO:40.93 ± 5.02; HYS:46.54 ± 3.48 |
Chongqing Haifu Technology | Rate of re-intervention (1 year); Days of hospital stay; Fever (2 days); Major adverse events (30 days) |
| Li et al. (21) | RCT | China | HIFU: 60 MYO (laparoscopic MYO): 60 |
HIFU:38.4 ± 5.4; MYO:39.3 ± 6.82 |
Chongqing Haifu Technology | Incidence of abnormal pregnancy (3 years); Days of hospital stay |
| Mohr-Sasson et al. (27) | Retrospective cohort study | Israel | HIFU: 68 MYO#(laparoscopic MYO): 64 |
HIFU:44(38–47); MYO:38(34–43) |
InSightec | Rate of re-intervention (31–36 months) |
| Wu et al. (28) | Retrospective cohort study | China | HIFU: 219 MYO (laparoscopic MYO): 224 |
HIFU:31.6 (22–42); MYO:32.4 (25–41) |
Chongqing Haifu Technology | Incidence of abnormal pregnancy (1–8 years) |
| Hu et al. (29) | Prospective cohort study | China | HIFU: 39 MYO (hysteroscopic MYO): 42 |
HIFU:43.0 ± 5.6 MYO:41.3 ± 4.4 |
Chongqing Haifu Technology | Days of hospital stay |
HIFU, high intensity focused ultrasound; UAE, uterine artery embolization; MYO, myomectomy; HYS, hysterectomy; RFA, radio frequency ablation.
*
Mean ± SD or Median(range).
#
In the myomectomy group, 29 women (45.3%) received robotically assisted laparoscopic myomectomy (Da Vinci Surgical system).